Mammography for screening, histopathology and blood tests for diagnosis, prognosis and treatment are considered gold standards for breast cancer.4 According to 2007 recommendations of ASCO for tumor markers ER, PgR and HER2 expression in primary invasive breast cancer should be evaluated for diagnosis or recurrence especially as a guide for therapy, while increasing levels of CA 27.29 or CA 15-3 may indicate treatment failure.5 This however cannot be applied to all breast tumors leaving a wide gap in our understanding of this heterogeneous tumor. The gene discussed is ERBB2; the disease is breast cancer.